CAH
Heads-up: USD Initial Jobless Claims is due in 1 h (high impact). The outlook can shift noticeably around it.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
CAH fundamental outlook?
From news analysis — different time windows than the trading horizons above
- Q1 fiscal 2027 non-GAAP EPS rose 28% to $3.26 on revenue of $67.5 billion, and Cardinal Health raised its full-year outlook — the highest-conviction catalyst in the signal set at 85% confidence.
- Non-GAAP operating earnings of $1.0 billion versus GAAP operating earnings of $753 million leaves a roughly $250 million adjusted-to-GAAP gap that warrants scrutiny on the quality of the beat.
- Revenue growth of 5% lagged EPS growth of 28%, confirming that margin expansion and the $5 billion buyback authorization — not top-line acceleration — are driving per-share results.
- CAH has outperformed Cencora by a wide margin over the past 52 weeks, posting roughly 60% growth while its closest peer lagged broader indices.
- The September 16 profit beat plus the $5 billion buyback increase and a Strong Buy consensus establish a mid-term floor under the stock ahead of the next earnings cycle.
- Jim Cramer's characterization of CAH as 'terrific' with strong earnings momentum at a lower valuation captures the healthcare sector rotation bid that has supported the name since September.
- The only non-bullish signal is a low-impact (2/10) neutral mention inside a Thermo Fisher upgrade article, which does not meaningfully offset the four bullish data points.
Cardinal Health enters November with strong fundamental momentum after Q1 fiscal 2027 results showed revenue up 5% to $67.5 billion, non-GAAP operating earnings up 17% to $1.0 billion, and non-GAAP diluted EPS up 28% to $3.26, prompting management to raise its full-year outlook. That November 5 release is the dominant signal in the set, carrying an impact score of 7 and 85% confidence, and it reinforces a year-long pattern of outperformance: CAH has gained roughly 60% over the past 52 weeks, well ahead of peer Cencora. The September 16 profit beat and $5 billion buyback authorization add a capital-return tailwind, while Jim Cramer's September 9 endorsement of 'terrific' earnings momentum at a lower valuation reflects the rotation into defensive healthcare distributors. The one offsetting detail is the GAAP-versus-adjusted gap — GAAP operating earnings of $753 million sit well below the $1.0 billion non-GAAP figure — and revenue growth of 5% trails the 17-28% earnings growth, meaning margin expansion and buybacks are doing the heavy lifting. The lone neutral signal, a passing mention in a Thermo Fisher upgrade piece, carries negligible weight. Net: four of five signals are bullish, the most recent is the strongest, and the narrative is coherent — earnings beats, raised guidance, and aggressive buybacks against a still-reasonable valuation.
11 min ago · Based on 5 signals
The raised fiscal 2027 guidance and 28% EPS beat should extend the post-earnings drift over the next week, with the stock holding above its pre-print base as analysts revise estimates upward. Watch for any pullback toward the pre-release level as a buying opportunity; a break below that zone on volume would signal the guidance raise was already priced in.
Over the next one to four weeks, the $5 billion buyback authorization and Strong Buy consensus provide a bid, while continued healthcare sector rotation favors defensive distributors with visible earnings. The key risk is multiple compression if the market rotates back toward higher-beta growth names, but the raised outlook gives CAH a cushion peers lack.
Structurally, CAH's 60% 52-week outperformance versus Cencora reflects durable share gains and margin discipline in pharmaceutical distribution, and the raised fiscal 2027 outlook supports earnings compounding into the next two quarters. The GAAP-versus-adjusted gap and 5% revenue growth are the structural watch items — if margin expansion stalls, the premium valuation built on 28% EPS growth becomes vulnerable.
Economic data for CAH
Full calendarRecently released
- November 4, 2026USDEIA Crude Oil Stocks Change●●●
- November 4, 2026USDISM Non-Manufacturing PMI●●●Forecast 55.2Previous 54.9
- November 4, 2026USDISM Non-Manufacturing Prices Paid●●●Forecast 69.5Previous 74.0
- November 4, 2026USDADP Nonfarm Employment Change●●●Forecast 64KPrevious 90K
- November 3, 2026USDJOLTS Job Openings●●●Forecast 6.779MPrevious 7.079M
- November 2, 2026USDISM Manufacturing Prices Paid●●●Forecast 80.7Previous 77.9
- November 2, 2026USDISM Manufacturing PMI●●●Forecast 54.7Previous 54.5
Coming up
- TodayUSDInitial Jobless Claims●●●in 1h
- TomorrowUSDAverage Hourly Earnings m/m●●●Forecast 0.2%Previous 0.1%in 1 day
- TomorrowUSDNonfarm Payrolls●●●Forecast 55KPrevious 29Kin 1 day
- TomorrowUSDUnemployment Rate●●●Forecast 4.2%Previous 4.2%in 1 day
- TomorrowUSDMichigan Consumer Sentiment●●●Forecast 48.5Previous 48.0in 1 day
- November 10, 2026USDCPI m/m●●●Forecast 0.5%Previous 0.6%in 5 days
- November 10, 2026USDCore CPI n.s.a. m/m●●●Previous 0.4%in 5 days
- November 10, 2026USDCore CPI●●●Forecast 339.796Previous 338.896in 5 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
What is being reported about CAH
📝 Overview Generated automatically?
CAH has been the subject of 5 signals across 5 articles in the last 365 days. Sentiment skews Bullish (80%).
Breakdown: 4 bullish, 0 bearish, 1 neutral. AI confidence averages 66% across all signals.
Most-cited catalysts: Strong relative market performance with 60% growth over the past year (1×), Q1 fiscal 2027 non-GAAP diluted EPS up 28% to $3.26 (1×), Non-GAAP operating earnings up 17% to $1.0 billion (1×). Most-cited risk factors: Potential for sector-wide volatility in pharmaceutical distribution (1×), Competitive pressure from peers like Cencora (1×), GAAP operating earnings of $753 million are well below non-GAAP operating earnings of $1.0 billion, so GAAP-versus-adjusted gap remains large (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.